MedTrace Logo

Probiotics in Alleviating Microplastic-Induced Obesity

NCT07416214 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2026-02-25

No results posted yet for this study

Summary

The study attempts to conduct randomized double-blind controlled trials to understand whether daily exposure to microplastics (MPs) can cause potential impacts on human health, explore whether the intake of Lactiplantibacillus plantarum PD01 can alleviate potential obesity-related damages caused by MPs, and provide a scientific basis for the prevention and nutritional intervention of health hazards caused by MP exposure.

Conditions

Interventions

DIETARY_SUPPLEMENT

Probiotics (Lactiplantibacillus plantarum PD01)

The probiotic supplement includes 0.2g Lactiplantibacillus plantarum FABYIO PD01 (containing 10 billion CFU) and 1.8g Fructooligosaccharides.

DIETARY_SUPPLEMENT

Placebo

The placebo includes 2.0g Fructooligosaccharides with an indistinguishable appearance and texture.

Sponsors & Collaborators

  • Xiamen Yueyi Biotechnology Co., Ltd.

    collaborator UNKNOWN

  • Fudan University

    lead OTHER

Principal Investigators

  • Ruihua Dong · School of Public Health，Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-30
Primary Completion
2026-01-12
Completion
2026-02-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07416214 on ClinicalTrials.gov